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Oral Psoralen Photochemotherapy of Atopic 
Eczema. WARWICK L. MORISON, M.D., JOHN A. 
PARRISH, M.D. AND THOMAS B. FITZPATRICK, 
M.D., Department of Dermatology, Harvard 
Medical School at the Massachusetts General 
Hospital, Boston, Massachusetts . 
Oral psora len photochemotherapy (PUV A) has 
been used for over two years in the treatment of 
psoriasis with good res ults. Beca use sunlight or 
artificial UVB is sometimes beneficial to patients 
with eczema, t he effect of PUV A on eczema has 
been investigated. Atopic eczema was chosen for 
the study because it presents a relatively clearly 
defined clinical picture. 
The t reatment consisted of ingestion of 8-
rnethoxypsoralen (0.6 mg/kg) and subsequent 
exposure, 2 hr later, to a meas ured dose of long-
wave ultraviolet light (UVA) in a high-intensity 
treatment system (Sylvania). Initially , treatment 
was administe red 3 times a week unt il the eczema 
had cleared; treatments were then reduced to 
weekly or bimonthly for the ma intenance phase. 
Initially 5 patients with generalized atop ic eczema 
were treated , control areas being kept covered in 2 
of the patients . It was found that t he eczema 
cleared with 11 to 58 treatments with no improve-
ment in the cont rol areas. Five patients, a lso with 
generali zed eczema, were then treated in a bilat-
eral co mparison study with PUV A given to one side 
of the body only. The treated side clea red with 16 
to 21 treatments while the untreated side remained 
un changed or showed deterioration. The untreated 
side was t hen cleared with PUV A. A further 
b ilateral co mpa rison stud y on 5 patients of PUVA 
versus UVB demonstrated t he superiori ty of 
PUV A. These patients have been kept free of 
eczema by weekly or every second week mainte-
nance treatment. 
Atopic eczema is a di sabling condi t ion in its 
severe form due to the cosmetic a ppearance, the 
severe pruritus, and the occurrence of secondary 
infections. Presently available therapy gives varia -
ble results and does not always achieve complete 
clearance of the eczema. Corti costeroids, either 
top ica lly or orally, may have marked side effects 
superimposing an iatrogenic disability. The pres-
ent controlled study indicates that PUV A is an 
effective t reatment not only resulting in total 
clearance of the eczema but a lso providing for a 
convenient, infrequent maintenance t reatment. 
Other forms of eczema may also respond to this 
therapy . 
Topical 6-Aminonicotinamide for Psoriasis. 
HERSCHEL S. ZACKHEIM, M.D., Depa rtment of 
Dermatology, Univers ity of California , School 
of Medicine , San Francisco, California. 
6-Aminonicotinamide (6-AN) is an ana log and 
potent antagonist of nicotinamide. It has been 
used in the t reatment of some experimental and 
human neoplasms, but may produce severe central 
nervous system (CNS) tox icity and damage to t he 
auditory nerve when given system ically in high 
doses. 
In an init ial double-blind study 1.5 % 6-AN in an 
acidified aqueous solut ion applied 2 or 3 times 
dail y without occlusion for 4 weeks resulted in 
marked improvement or complete clearing of pso-
riatic plaques in 27 of 34 patients. None of the 
plaq ues treated with the vehicl e alone showed this 
degree of improvement. In a second study, the 
effect of 1 % 6-AN was compared to that of 0.1 % 
triamcinolone (TAC), both in a gel base, appl ied 
without occlusion 2 or 3 t imes daily for 4 weeks . In 
22 patients the effect of 6-AN was superior to TAC 
in 19, equa l in 2, and in fe rior in 1. There was 
marked improvement or complete clearing of 
lesions in 18 patients treated with 6-AN, but in 
only 3 treated with TAC . 
Contact dermat itis occurred in 9 of 56 patients 
t rea ted with 6-AN. Of these, 3 were judged to be 
hypersensit ivity reactions and 6 irritant dermati -
t is. Cutaneous "toxic" reactions, remote from the 
6-AN applications, occurred in 10 of 56 pat ients. 
These include angular cheili t is, cant hitis, dermati -
tis of the face and ax illae. There was one instance 
of photophobia. No signs of CNS toxicity or 
changes in a udiogra ms taken for up to 2 years were 
noted. These side effects are suggestive of aribo-
fl av inos is or a mixed B-complex deficiency. Pella-
gra -like signs were not seen. 
Topical 6-AN is a remarkably effective agent in 
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clearing psoriasis . More experience is necessary to 
further define its value and hazards . It is approved 
for investigational use on ly. 
Analysis of the Goeckerman Regimen in Psoria-
sis. JOHN W. PETROZZI, M.D., KAYS KAIDBEY, 
M.D., ALBERT KLIGMAN, M.D., Ph.D., Depart-
ment of Dermatology, Veterans Administra-
tion Hospital, Philadelphia, Pennsylvania. 
Since so many variables exist in administering 
the Goeckerman treatment for psoriasis, this study 
was undertaken to establish a standardized treat-
ment schedule. The objects of the study included 
determination of the most effective type of tar, con-
centration, vehicle, light source, and interval from 
time of application to irradiation. 
Patients were se lected with chronic stable 
plaque-type psoriasis. Paired symmetrical plaq ues 
were treated so that crude coal tar was compared to 
Estar gel, pine tar, ichthammol , LCD, and tar 
distillate; concentrations of 1 %, 5%, and 25 % crude 
coal tar were compared. As a vehicle for tar, 
hydrophilic ointment was compared to petrolatum, 
vanishing cream, and Carbowax. Irradiation with a 
bank ofUVB bulbs was compared to a similar bank 
of UV A; overnight tar application was compared to 
tar applied 2 hr before light exposure. 
Our results indicated that crude coal tar was su-
perior. A 5% concentration in hydrophilic ointment 
was optimal; UVB irradiation worked faster than 
UV A, and tar applied 2 hr prior to irradiation did as 
well as overnight. Thus, we conclude that with the 
use of the above the Goeckerman treatment can be 
simplified and made more acceptable for outpa-
tient use . 
Epidermal Nuclear IgG Deposition: Correlation 
of Clinical Features and Laboratory Find-
ings in 32 Patients. STEPHEN D. PRYSTOWSKY, 
M .D., AND DENNY L. TUFFANELLI, M.D. , 
Department of Dermatology Research, Letter-
man Army Institute of Research , and The 
Department of Dermatology, University of 
California School of Medicine, San Francisco, 
California. 
Deposition of immunoglobulin (IgG) in epider-
mal nuclei has recently been associated with high 
titer serum antibody to extractable nuclear antigen 
(ENA). The purpose of this study is to correlate 
the clinical and laboratory features of this distinct 
immunopathologic finding in a large group of 
patients. 
Thirty-two patients with IgG loca li zation in 
epidermal nuclei on direct immunofluorescence of 
uninvolved skin have been studied. The clinical 
diagnoses were mixed connective tissue disease or 
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overlap syndrome (72%), SLE (25%), and prones-
tyl induced LE (3%). 
Cutaneous manifestations included: sclerodac-
tyly (41%), cutaneous LE (38%), alopecia (38%), 
periungual erythema or telangiectasia (28%), and 
dyspigmentation (22%). Systemic manifestations 
included: arthritis or arthralgia (91%), Raynaud's , 
(78%), esophageal dysmotility (56%), myositis 
(50%), serositis (40%), adenopathy (31%), sicca 
syndrome (25 %), prolonged hoarseness (19%), 
migraine headaches (16%), and mild renal disease 
(12%). 
The pattern of epidermal nuclear staining was 
always speckled. The lupus band test was posi-
t ive in 25%. High-titer (mean = 1:220,380) serum 
antibody to ENA was found in 83 % of patients. 
Eighty-three percent had antibody to an RNase-
sensitive antigenic component of EN A (ribonucleo-
protein or RNP); 17% had antibody to an RN ase-
resistant ENA termed Sm. Other positive labora-
tory findings included: ANA (97 %), abnormal 
pulmonary function tests (66%), hypergamma-
globulinemia (65 %), rheumatoid factor (55 %), LE 
prep (46%), hypocomplementemia (37 %), Coombs 
test positive (32 %), and anti-nDNA (19 %). 
Deposition of speckled IgG in ep idermal nuclei is 
an immunopathologic marker for a subset of con-
nective t issue disease characterized by antibody to 
ENA. Those with Sm specificity had classical LE. 
Those with RNP specificity usually had overlap-
ping features of SLE, scleroderma , and der-
matomyositis. 
Unique Melanoma Proteins: Distinct Charac-
teristics Which Are Possibly Related to 
Immunogenicity. W. G. KLINGLER, M.D., S. 
KERNEY, B.A., P. M. MONTAQUE, B.A. , J. M. 
NICHOLSON, PH.D., P. B. CHRETIEN, M.D., T. 
M. EKEL, B.A., AND V. J. HEARING, PH.D., 
Department of Dermatology, University of 
North Carolina, Chapel Hill , North Carolina, 
and National Cancer Institute, National Insti -
tutes of Health, Bethesda, Maryland. 
Host immunologic responses against malignant 
melanoma have been implicated in spontaneous 
regress ions and prolonged remissions seen clini -
cally. In addition , immunologic differences 
between normal and malignant melanocytes have 
been shown, and significant macrophage migration 
inhibition (MI) using either whole or protein ex-
tracts of malignant melanocytes has heen demon-
strated. Many aberrations of normal melanogene-
sis have been established at ultrastructural and 
biochemical levels in melanoma melanocytes. This 
study compared the melanosomal protein composi-
tions of normal and malignant pigment cell s in 
order to determine whether the known ultrastruc-
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t u ral a lterations of melanin granules are ev idenced 
bY the presence of a berra nt proteins capable of 
elicit ing MI. Normal melanosomes were obta ined 
{r o m human choroid and murine (C57 black) skin 
I:lnd eye, while t hose from malignant t issues were 
obtain ed from human and murine (B-16 and S-91) 
melanomas. Fo llowin g puri fication by sucrose den-
s i ty gradien t cen t ri fugation, melanin granules were 
solubili zed in 1% T ri ton X-IOO, then fractionated 
bY polyacrylamide gel electrophores is (PAGE ). 
Molecular size and charge of individual melanoso-
ma l prote ins were then determined. T he leuko-
cytes of normal and tumor-bearing individuals 
were assayed fo r MI in response to various subcel-
1 ular fractio ns of normal and malignant melano-
cytes includ ing purified melanosomes. A compari-
son by P AGE of normal and malignant melanoso-
mal prote in bandin g patterns in each animal 
syste m demonstrated: (1) proteins unique to mela-
n oma, (2) prote ins restricted to norma l melano-
somes, and (3) prote ins common to normal and 
malignant t issues. Most unique human melanoma 
melanosomal proteins have an analogous un ique 
m urine melanoma prote in which corresponds with 
regard to both molecular weight and charge. Leu-
kocytes of tumor-bearing individuals, monitored 
by MI assays, were most markedly inhibi ted in 
m igration in response to native or to solubili zed 
m elanoma melanosomes but not to normal mel-
a nosomes; leukocytes from normal individuals 
w ere not inhibited using fractions from either ma-
ligna nt or normal ant igen sources. Further study of 
s uch unique melanoma melanosoma l prote ins 
could provide insight into the mechanism of spon-
taneous resolut ions of this tumor. 
Photochemotherapy for Mycosis Fungoides. 
H ENRY H . ROENIGK, JR., M .D ., The Cleveland 
Clinic Foundation, Cleveland , Ohio. 
Mycosis fungo ides is a malignant lymphoma 
a ris ing in t he skin wit h progression to plaques and 
t umors. Visceral lymphoma after many years even-
t uates in death. Past t herapy of mycos is fun go ides 
h as included topica l cort icosteroids, ni trogen mus-
tard pain t ing, and electron bea m radiation. 
M ethoxsalen combined wit h phototherapy us ing 
high-in te ns ive long-wave (320-390 nm) ul t rav iolet 
light uni ts has been successful in t he treatment 
of psorias is. 
T welve cases of cutaneous mycos is fungo ides 
wit h erythroderma, plaques, a nd t umors were 
treated wit h photochemotherapy. All les ions 
cleared with photochemothera py, except a few 
tumors. P hototherapy units consisted of boxes wit h 
16 to 64 UVA lights. T he average nu mber of 
t reatments to clear was 19.4. T he average dose of 
UVA at t im e of clearing was 5.6 joules/cm 2. Histo-
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pathologic clea ring corresponded to clinical clear-
ing of lesions. 
P hotochemotherapy may inhibit t umors of 
;-!)ycosis fu ngoides due to inhibit ion of DNA and 
RNA synthesis. 
Pha rmacokinetics of I n t r a muscular and 
Intravenous [14C lProcaine and [14C jPr o-
caine P enicillin G. T HOMAS F. D OWNH AM II, 
M.D., Depart ment of Dermatology, Wayne 
State University, Detroit, Michigan. 
Fear of impending death, visual, aud itory, and 
gustatory disturbances, cardiovascular changes , 
violent behavioral disturbances and grand ma l 
seizures are the main sym ptoms and signs of a 
systemic tox ic reaction during adm inistration of an 
int ra muscular injection of procaine pen ic illin G. 
The sy m ptoms and signs closely parallel systemic 
tox ic reactions to local anesthetics and usually 
subside in 2 to 10 min spontaneously or after 
t reatment. P rocaine penicillin G may enter the 
circulation following intramuscular injection due 
to inadvertent intravenous administration . 
T he study was designed to determine t he rate of 
up take of [14C ]procaine and ["C jprocaine pen icil-
lin G from plasma to cerebral spinal fl uid (CSF) in 
dogs following int ramuscular and intravenous in-
jec tion of 45 /-L Ci of labeled drug. 
Nineteen mongrel, adul t male dogs were anes-
thetized with an init ia l in t ravenous dose of pen -
tobarbita l. Artificial respiration was monitored 
through a cuffed endotracheal t ube wit h a respira-
tor . Indwelling catheters in t he cisterna magna, 
fe moral artery, and bladder allowed collection of 
CSF, blood and urine over 2- and 3-hr interva ls. 
Radioactiv ity (dpm/ml) of 14C in the samples was 
determined wit h a liquid scint illation system . 
Pharmacokinetic analysis of t he " washout" and 
" uptake" curves yielded t he fo llowing half-t imes: 
In t ramuscular 
Plasma " uptake" 
CSF " uptake" 
In t ravenous 
P lasma "washout" 
CSF " uptake" 













Following int ravenous, as compared to intra-
muscular, administration of ('·C jprocaine penicil-
lin G, rapid uptake from plasma to CSF is indi-
cated by the half-t ime value . Ti me course d istri bu-
tion of ["C ]proca ine penicillin G para llels t he 
clinical t ime course of systemic toxic reactions. 
The data support the hypothesis t hat inadverten t 
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intravenous administration of procaine penicillin 
G must occur in a clinical setting in order to 
produce the symptoms and signs of a systemic 
toxic reaction. Procaine is the probable inciting 
agent . 
Studies of Human Wart Virus in Tissue Culture. 
M. EISINGER, D .V.M., Memorial Sloan-Ket-
tering Cancer Center, New York, New York. 
Human warts and papillomas are one of the 
most common cutaneous disorders . However, even 
though their etiology has been known for more 
than a half century, detailed studies of the virus 
have been hampered by the lack of a system in 
which to propagate the virus. We have recently 
developed a tissue culture system for the growth of 
the human wart virus in vitro. We have found that 
only human epidermal cells can be lytically in-
fected. Un cloned epithelial cell s derived from 
human skin may, however, also become chron i-
cally infected, with little or no virus release. Since 
virus quantitation, in the tissue culture system, 
based on cytopathogenicity of the virus cannot be 
relied upon, a very sensitive method of comple-
ment fixation based on Cr· 1 release has been 
adapted . Using this system we have found anti-
genic identity between the hand wart and plantar 
wart virus isolates, and we are now approaching 
the question of antigenic differences between virus 
isolates from different human papillomas. Since 
these viruses are believed to have also oncogenic 
potential, our studies of tumor-associated antigens 
will be presented . 
Phosphonoacetic Acid Treatment of Herpes 
Simplex Infections in Guinea-Pig Skin. 
JAMES R. McCARTY, M .D., AND MICHAEL JAR-
RATI, M.D., Department of Dermatology, 
Baylor College of Medicine, Houston, Texas. 
Phosphonoacetic acid (PPA) was evaluated as 
therapy for primary herpes simplex virus (HSV) 
infections in guinea-pig skin. 
Epilated areas of skin were inoculated with HSV 
type 1. These areas were treated in a blind fashion 
with topical PPA 2% cream or placebo cream, the 
initial application varying from 3 to 84 hr after 
inoculation. 
Treatment with PPA beginning 3 hr after inocu-
lation inhibited vesicle formation. Treatment 
beginning from 12 to 84 hr after inoculation caused 
a marked reduction in vesicle formation, with 
placebo-treated sites showing typical lesions. Ani-
mals treated 3 times daily demonstrated a primary 
irritant reaction to PPA, but not to placebo; 
irritancy was not seen in animals treated twice 
daily. 
PPA applied 3 hr after inoculation probably 
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aborts the infectious process by killing extracellU-
lar virus . PPA reduces the manifestations of pri-
mary HSV type 1 infections in guinea-pig skin, 
even when applied concurrently with the appear-
ance of lesions 84 hr after inoculation, and thus 
may be suitable for treatment of human HSY 
infections. However, a dose-related primary irfl-
tant effect is to be avoided. 
Deficiency in the Second Component of Comple-
ment and Lupus Erythematosus. STANLEY B. 
LEVY, M .D., SHELDON R. PINNELL, M.D. , 
RALPH SNYDERMAN, M.D., AND FRANCES WARD, 
PH.D., Division of Dermatology and Division 
of Immunology, Department of Medicine, 
Duke University Medical Center, Durham, 
North Carolina. 
Selective congenital deficiency in the second 
component of complement has recently been de-
scribed in association with lupus erythematosus, 
dermatomyositis , and vasculitis in addition to 
being found in healthy normals. We identified a 60-
year-old white female with a 13-year history of 
cutaneous lupus erythematosus and no detectable. 
serum C2. The patient's photosensitivity, lack of 
renal disease, absent antinuclear antibodies, high 
incidence of bacterial infection, and absence of C3 
on direct immunofluorescent examination of 
involved skin is consistent with previously reported 
patients with th is association . Immunologic stud-
ies, including quantitative immunoglobulins , skin 
tests, lymphocyte transformation , monocyte 
chemotaxis, chemotactic lymphokines, and T - and 
B-cell assays revealed depression in both humoral 
and cellular immunity. Moderation in her clinical 
disease and the above immunologic parameters 
has been observed after treatment with levamisole. 
Immunogenetic studies of the patient's kindred, 
which included four generations, was consistent 
with an autosomal recessive form of inheritance of 
C2 deficiency. Correlation of complement assays of 
family members with HLA typing revealed that 
relatives sharing one haplotype with the C2-defi-
cient propositus (2-18 or 25-18) had partial defi-
ciency of C2. Genetic linkage is demonstrated 
between BI8 and C2 deficiency. Mixed lymphocyte 
culture determinations in this and previously re-
ported kindreds are reviewed in an attempt to map 
the gene controlling the elaboration of C2. 
Vasculitis in Granuloma Annulare. MARK V. 
DAHL, M.D., SUSANNE ULLMAN, M.D., AND 
ROBERT W. GOLTZ, M.D ., Department of Der-
matology, University of Minnesota, Min-
neapolis, Minnesota. 
Since biopsies from lesions of granuloma 
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annulare frequently show blood vessel thickening, 
biopsies from patients with granuloma annulare 
were studied by conventional light and immuno-
fluorescence microscopy. IgM was present in blood 
vessels of involved skin from 6 of 20 patients, and 
C3 was present in blood vessels in 10 of 20 patients . 
In addition, IgM, C3, or fibrinogen were observed 
at the dermal- epidermal junction of 8 patients. 
Necrobiotic areas contained fibrinogen. A retro-
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spective histopathologic study of 38 biopsy speci-
mens from other patients with granuloma annulare 
showed blood vessels with vessel wall necrosis, 
fibrinoid change, thickening, or occlusion in most 
specimens. Nuclear dust and extravasation of red 
blood cells were also noted. These findings suggest 
that an immunoglobulin-mediated vasculitis may 
be involved in the pathogenesis of granuloma 
annulare. 
